Advice
in the absence of a submission from the holder of the marketing authorisation:
trastuzumab deruxtecan (Enhertu®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice237KB (PDF)
Medicine details
- Medicine name:
- trastuzumab deruxtecan (Enhertu)
- SMC ID:
- SMC2693
- Indication:
As monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 July 2024